1-3 of 3
biological response modifiers
Close
Sort by
Journal Articles

Metaphase cytogenetics and plasma cell proliferation index for risk stratification in newly diagnosed multiple myeloma

Patrick W. Mellors, Moritz Binder, Rhett P. Ketterling, Patricia T. Greipp, Linda B. Baughn, Jess F. Peterson, Dragan Jevremovic, Kathryn E. Pearce, Francis K. Buadi, Martha Q. Lacy, Morie A. Gertz, Angela Dispenzieri, Suzanne R. Hayman, Prashant Kapoor, Wilson I. Gonsalves, Yi L. Hwa, Amie Fonder, Miriam Hobbs, Taxiarchis Kourelis, Rahma Warsame, John A. Lust, Nelson Leung, Ronald S. Go, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2236–2244.
https://doi.org/10.1182/bloodadvances.2019001275
Published: 2020
Includes: Supplemental data
Journal Articles

Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents

Clinical Trials & Observations
Smith Giri, Scott F. Huntington, Rong Wang, Amer M. Zeidan, Nikolai Podoltsev, Steven D. Gore, Xiaomei Ma, Cary P. Gross, Amy J. Davidoff, Natalia Neparidze
Journal: Blood Advances
Blood Adv (2020) 4 (10): 2245–2253.
https://doi.org/10.1182/bloodadvances.2019001425
Published: 2020
Journal Articles

Integrative analysis of the genomic and transcriptomic landscape of double-refractory multiple myeloma

Bachisio Ziccheddu, Giulia Biancon, Filippo Bagnoli, Chiara De Philippis, Francesco Maura, Even H. Rustad, Matteo Dugo, Andrea Devecchi, Loris De Cecco, Marialuisa Sensi, Carolina Terragna, Marina Martello, Tina Bagratuni, Efstathios Kastritis, Meletios A. Dimopoulos, Michele Cavo, Cristiana Carniti, Vittorio Montefusco, Paolo Corradini, Niccolo Bolli
Journal: Blood Advances
Blood Adv (2020) 4 (5): 830–844.
https://doi.org/10.1182/bloodadvances.2019000779
Published: 2020
Includes: Supplemental data